Astellas’ Xospata (gilteritinib) Receives Health Canada Approval for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

 Astellas’ Xospata (gilteritinib) Receives Health Canada Approval for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

Astellas’ Xospata (gilteritinib) Receives Health Canada Approval for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

Shots:

  • The approval is based on P-III ADMIRAL study assessing Xospata (120mg) vs salvage CT in 371 patients in a ratio (2:1) with r/r AML and FLT3 mutation in bone marrow or in whole blood
  • The P-III ADMIRAL study results demonstrated longer OS (9.3 vs 5.6mos.), rate of survival @1yr. (37% vs 17%)
  • Xospata is the first and only targeted treatment approved by Health Canada for r/r AML with FLT3 mutation and has received approval in the US and Japan in 2018 and in EU in 2019

Click here ­to­ read full press release/ article | Ref: Newswire Canda | Image: STAT News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post